Targeted Disease(s):
COPD

Purpose of Study:

Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD

Study Dates:
December 16, 2020 - November 28, 2025

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Sanofi and Regeneron

Sponsors:

Sanofi

Contact:

Phone: 800-633-1610, option 6
Email: [email protected]

ClinicalTrails.gov Identifier:
NCT04701983

Register for Trial
Asthma Basics Workshop - National
, | Mar 20, 2024
Asthma Basics Workshop - National
, | Apr 17, 2024